Cognitive & Brain Health
An advanced screening panel to assess early biological changes linked to brain aging, cognitive decline, and neurodegenerative risk using blood biomarkers and optional genetic insights.
What This Measures
Plasma Beta-Amyloid (Aβ42/40)
Measures proteins linked to amyloid plaque buildup in the brain, one of the earliest known signs associated with Alzheimer’s disease.
Plasma Tau (p-tau)
Detects abnormal tau protein activity in the bloodstream, a biomarker that may indicate early neurodegeneration and cognitive decline.
Neurofilament Light Chain (NfL)
Assesses a highly sensitive marker of nerve cell damage and brain inflammation; elevated levels can reflect ongoing neurological stress, injury, or axonal breakdown.
ApoE Genotyping (Optional, doctor-guided)
Analyzes the ApoE gene, which can influence an individual’s inherited risk of developing Alzheimer’s disease and cognitive decline later in life.
Why It's Important
- Many neurological conditions develop silently over 10 to 20 years before symptoms or noticeable memory changes appear.
- This panel helps identify early biological signs of accelerated brain aging.
- It can indicate increased risk or early markers of cognitive decline.
- It may reveal potential underlying neurodegenerative changes.
- It can detect unseen neurological stress or brain inflammation.
- It can surface inherited genetic predisposition to Alzheimer’s disease.
Potential Benefits
- Earlier awareness of hidden cognitive health risks long before symptoms surface.
- Opportunity for proactive, targeted lifestyle, sleep, and medical interventions.
- Supports long-term brain performance, cognitive reserve, and healthy aging.
- Helps guide personalized, data-driven prevention strategies.
- Peace of mind through deeper visibility into long-term neurological health.
Who May Benefit Most
- Individuals with a family history of Alzheimer’s disease, dementia, or cognitive decline.
- People noticing subtle early changes in memory, focus, or concentration.
- Those in high-stress, sleep-deprived, or cognitively demanding roles.
- Individuals focused on proactive longevity and brain health optimization.
- Anyone seeking an objective, advanced baseline check of their neurological system.
Important to Know
- This is a risk assessment and monitoring tool, not a definitive standalone diagnosis for dementia or Alzheimer’s disease.
- Results should be interpreted alongside clinical context, cognitive testing, and medical guidance.
- Genetic testing (ApoE) is optional, provides risk probability rather than certainty, and is typically recommended in consultation with a healthcare professional.